SHAPING THE FUTURE OF
BIOMIMETIC STENTS

biomimics-logo

biomimicry

n (Life Sciences & Allied Applications / Biology) the mimicking of life using imitation biological systems

Management Team

Chas Taylor

CEO, Executive Director

Chas has over 20 years’ experience in the medical device industry. He has been involved in successful medical device start-up companies since 1996. He co-founded embolic filter and carotid stent specialists MedNova which was acquired by Abbott in 2005. Before this he worked with CR Bard for twelve years in various sales, marketing and general management roles. During this time he was based in the USA for eight years in senior positions including Vice-President for Bard Cardiovascular.


 

Paul Gilson

CSO

Paul also has over 20 years’ experience in the medical device industry. He was a co-founder and General Manager of MedNova and was responsible for the development of innovative carotid technologies. Prior to his experience in start-up companies he held a number of senior roles in Operations, Development and R&D. He was Director of R&D for Bard Cardiology where he developed numerous cardiovascular devices. He is the holder of more than 20 patents for biomaterials and cardiovascular products.


 

Nick Yeo

COO

Nick has over 20 years’ international experience in the healthcare industry. He began his career in pharmaceuticals, becoming CEO of Sterling Winthrop Prescription Medicines, before moving on to senior marketing and business leadership roles at Gensia Europe and Scotia QuantaNova. Before joining Veryan he held senior management positions in product and clinical development at oncology drug-device specialist Light Sciences, where he led the formation of a cardiovascular technology start-up.